ST. LOUIS, MO--(Marketwire - June 21, 2010) - Mobius Therapeutics™, LLC has received notice of allowance from the United States Patent and Trademark Office on the core patent protecting its platform product, Optomycin™. Optomycin™ is an innovative product that provides for extended, on-site storage of ophthalmic mitomycin-c. Together with a closed handling system, Optomycin™ permits safe and efficient delivery of a precise, single dose of ophthalmic mitomycin. It is currently awaiting regulatory approval.
"We have long believed that the unique convenience and presentation offered by Optomycin™ is without precedent and this notice of allowance is further confirmation," said Ed Timm, President of Mobius Therapeutics™. "As we approach product launch, this patent protection along with the orphan drug status for glaucoma surgery will provide a strong foundation for Mobius™."
About Mobius Therapeutics™
Mobius Therapeutics™, LLC is an early stage venture focused on ophthalmic surgery solutions. Its first product, Optomycin™, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. Additional product applications are in earlier stages of development.